UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB


     /x/ QUARTERLY  REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

                  FOR QUARTERLY PERIOD ENDED SEPTEMBER 30, 2003

                                       OR


     / / TRANSITION  REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

                   FOR THE TRANSITION PERIOD FROM_____ TO____.

                         COMMISSION FILE NUMBER 0-49824

                           INAMCO INTERNATIONAL, CORP.

        (Exact name of small business issuer as specified in its charter)

                 DELAWARE                               72-1359595
      (STATE OR OTHER JURISDICTION OF                (I.R.S. EMPLOYER
      INCORPORATION OR ORGANIZATION)               IDENTIFICATION NO.)

  801 Montrose Ave., South Plainfield, NJ                 07080
           (ADDRESS OF PRINCIPAL                        (ZIP CODE)
            EXECUTIVE OFFICES)

                                 (908) 754-4880
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes /x / No / /

    Indicate the number of shares outstanding of each of issuer's classes of
                common stock, as of the latest practicable date.

    COMMON STOCK, $0.00001
           PAR VALUE                                 4,994,633 SHARES
 ----------------------------------          ----------------------------------
            Class                            Outstanding as of November 19, 2003




<PAGE>



                           INAMCO INTERNATIONAL, CORP.
                         (A Development Stage Company)
                                      INDEX
<TABLE>
<CAPTION>
                                                                                                   PAGE
                                                                                                    NO.
                                                                                                  ------
                                      PART I. FINANCIAL INFORMATION
<S>         <C>                                                                                       <C>
Item 1.      Financial Statements (Unaudited)                                                          3

             Condensed Balance Sheets--As of September 30, 2003 and December 31, 2002                  3

             Condensed Statements of Operations--Three and Nine Month Ended September 30, 2003         4
             and 2002

             Condensed Statements of Cash Flows--Nine Month  Ended September 30, 2003 and 2002         5

             Notes to Condensed Financial Statements                                                   6

Item 2.      Management's Discussion and Analysis of Financial Condition and Results of                8
             Operations

Item 3.      Controls and Procedures                                                                  10

                                        PART II. OTHER INFORMATION

Item 4.      Exhibits and Reports on Form 8-K                                                         11

Signatures                                                                                            11
Exhibit 31                                                                                            12
Exhibit 32                                                                                            13

</TABLE>




                                        2
<PAGE>



PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS


                           Inamco International, Corp.
                         (A Development Stage Company)
                            Condensed Balance Sheets

<TABLE>
<CAPTION>
                                                             September 30,  December 31,
                                                                  2003           2002
                                                             -------------  ------------
                                                               (unaudited)      (Note)
ASSETS
Current assets:
<S>                                                         <C>            <C>
  Cash .................................................     $          92  $        927
                                                             -------------  ------------
   Total Current Assets ................................                92           927
  Other Assets .........................................     $         213  $        213
                                                             -------------  ------------
Total Assets ...........................................     $         305  $      1,140
                                                             =============  ============
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current liabilities:
  Accounts payable and accrued expenses ................     $      10,189  $      5,615
                                                             -------------  ------------
   Total Current liabilities ...........................            10.189         5,615
  Due to Officers/Shareholders .........................            20,123         8,069
                                                             -------------  ------------
   Total Liabilities ...................................            30,312        13,684
Stockholders' Deficiency:
  Common stock, $0.00001 par value;
  Authorized: 50,000,000 shares
  Issued and Outstanding: 27,600,000 shares ............               276           276
  Additional paid-in capital ...........................            22,804        22,804
  Deficit Accumulated in the Development Stage .........           (53,087)      (35,624)
                                                              -------------  ------------
Total Stockholders' Deficiency .........................           (30,007)      (12,544)
                                                              -------------  ------------
Total liabilities and stockholders' equity .............     $         305  $      1,140
                                                             =============  ============
</TABLE>

Note:    These balance sheets have been derived from unaudited financial
         statements and do not include all of the information and footnotes
         required by accounting principles generally accepted in the Unites
         States for complete financial statements.

See accompanying notes to condensed financial statements.



                                        3
<PAGE>

                           Inamco International, Corp.
                         (A Development Stage Company)
                       Condensed Statements of Operations
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                    Three months ended
                                                                      September 30,
                                                            ------------------------------
                                                                 2003              2002
                                                            ------------      ------------

<S>                                                        <C>               <C>
Revenues
  Total revenues .........................................  $         -       $          -

Cost and Expenses
Bank Charges and Miscellaneous ...........................            44                39
Professional and Consulting Fees .........................         7,987                 -
                                                            ------------      ------------
  Total operating expenses ...............................         8,031                39
  Net Loss ...............................................  $     (8,031)     $        (39)
                                                            ============      ============
Net (loss) per share .....................................  $      (0.00)     $      (0.00)
                                                            ============      ============

Weighted Average Number of Shares Outstanding ............    27,600,000        27,600,000
                                                            ============      ============

</TABLE>

<TABLE>
<CAPTION>

                                                                   Nine months ended
                                                                     September 30,
                                                            ------------------------------
                                                                2003              2002
                                                            ------------      ------------
<S>                                                       <C>               <C>
Revenues
  Total revenues ........................................   $          -      $          -

Cost and Expenses
Bank Charges and Miscellaneous ..........................            134               539
Professional and Consulting Fees ........................         17,329                 -
                                                            ------------      ------------
  Total operating expenses ..............................         17,463               539
  Net Loss ..............................................   $    (17,463)     $       (539)
                                                            ============      ============
Net (loss) per share ....................................   $      (0.00)     $      (0.00)
                                                            ============      ============
Weighted Average Number of Shares Outstanding ...........     27,600,000        27,600,000
                                                            ============      ============
</TABLE>

See accompanying notes to condensed financial statements.







                                        4
<PAGE>


                                                Inamco International, Corp.
                                               (A Development Stage Company)

                                            Condensed Statements of Operations
                                                        (Unaudited)




<TABLE>
<CAPTION>

                                                                 Inception (January 17
                                                                1993) to September 30,
                                                                 ---------------------
                                                                          2003
                                                                 ---------------------
              <S>                                              <C>
               Revenues
                 Total revenues ............................... $                    -

               Cost and Expenses
                Bank Charges and Miscellaneous .................                   307
                Professional and Consulting Fees ...............                52,779
                                                                ----------------------
                 Total operating expenses ......................                53,086
                 Net Loss ......................................$              (53,806)
                                                                ======================
                Net (loss) per share ...........................$                (0.00)
                                                                ======================
               Weighted Average Number of Shares Outstanding                14,932,480
                                                                ======================

</TABLE>


                   Condensed Cash Flow Statements (Unaudited)

<TABLE>
<CAPTION>
                                                           Nine months ended September 30,
                                                           -------------------------------
                                                                2003             2002
                                                           -------------      ------------
<S>                                                        <C>                <C>
Cash Flows from Operating Activities
Net income (loss) ......................................... $     (17,463)    $       (539)
Adjustments to reconcile net loss to net cash used
in operating activities: ..................................             -                -
  Change in accrued expenses ..............................         4,574           (1,668)
                                                           -------------      ------------
Net cash used for operating activities ....................       (12,889)          (2,192)

Cash Flows from Investing Activities
  Change in other assets ..................................             -                -
Net cash used for investing activities ....................             -                -

Cash Flows from Financing Activities
  Loans from officer/shareholder, net of repayments .......        12,054            2,168
  Restricted common stock issued in payment of
  expenses ................................................            --                -
                                                           -------------      ------------
Net cash provided by financing activities .................        12,054            2,168
NET INCREASE (DECREASE) IN CASH ...........................          (835)             (24)
Cash at beginning of period ...............................           927               38
                                                           -------------      ------------
Cash at end of period ..................................... $         92      $         14
                                                           =============      ============

</TABLE>

See accompanying notes to condensed financial statements.



                                        5
<PAGE>




NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

1. Basis of Presentation

     In the opinion of management,  all  adjustments,  consisting only of normal
recurring  adjustments  necessary  for  a  fair  statement  of  (a)  results  of
operations  for the nine and three month  periods  ended  September 30, 2003 and
2002 (b) the financial position at September 30, 2003, and (c) the statements of
cash flows for the nine month period ended September 30, 2003 and 2002 have been
made.  The results of operations  for the nine and three months ended  September
30, 2003 are not  necessarily  indicative  of the results to be expected for the
full year.

     The  accompanying  unaudited  financial  statements  have been  prepared in
accordance with generally accepted  accounting  principles for interim financial
information.  Accordingly, they do not include all the information and footnotes
required by generally accepted accounting  principles for financial  statements.
For further  information,  refer to the audited  financial  statements and notes
thereto for the year ended  December  31, 2002  included in the  Company's  Form
10-KSB filed with the Securities and Exchange Commission on April 15, 2003.

     The  preparation  of financial  statements  in accordance  with  accounting
principles  generally accepted in the United States requires  management to make
estimates  and  assumptions  that  affect  amounts  reported  in  the  condensed
financial statements and related footnotes.  Changes in the estimates may affect
amounts reported in future periods.

     The company is in the development  stage as defined I Financial  Accounting
Standards Board Statement NO. 7. It has not commenced full scale  operations and
has  insignificant  assets.  The financial  statements  have been presented on a
going  concern  basis,  which  contemplates  the  realization  of assets and the
satisfaction of liabilities in the normal course of business. The Company has no
significant assets, no revenues and has had losses since inception.  The Company
can only  become a viable  going  concern if it obtains  additional  capital and
acquires a viable operating company.

2. Net Loss Per Share

     In accordance  with SFAS No. 128,  Earnings Per Share basic and diluted net
loss per share  are  computed  by  dividing  the net loss for the  period by the
weighted average number of common shares outstanding during the period.

3. Comprehensive Loss

    Comprehensive loss for all periods presented is the same as net loss.

4. Deferred Stock Compensation

     For the nine months ended  September 30, 2003 and 2002, in connection  with
advisory  and  consultation  to second  party  firms,  the  Company  recorded no
deferred stock compensation.


5. Non-cash Preferred Stock Charge

     For the nine months ended September 30, 2003 and 2002, the Company recorded
no sale of any forms of Preferred Stock.

6. Capital Purchase of Common Stock by a Privately Held Business

     On October  26,  1999,  the  Company,  which was  previously  known as Omni
Assets,  Inc. (a  "non-operating"  public shell),  sold 22,273,890 of its common
shares of stock to Inamco  International  Corp. (a privately held  corporation).
The  acquisition  was  deemed  to  be a  capital  purchase,  by  privately  held
corporations, of the majority amount of common shares owned by Omni Assets, Inc.

                                       6
<PAGE>

In January 2000,Omni then purchased the name of "Inamco  International  Corp." ,
and in February  2000, the Company  changed it name from "Omni Assets,  Inc." to
"Inamco  International  Corp.".  The listing  symbol was changed  from "OMNA" to
"IICO".  The Company  subsequently  performed a 1-for-1000  reverse split of its
common  share of stock,  effective  October 2, 2003,  thus  causing  its listing
symbol to change from "IICO" to "IICC".  As of September 30, 2003  however,  the
total number of shares  outstanding  equaled  Twenty  Seven  Million Six Hundred
Thousand (27,600,000).

     The following table provides information  pertaining to owners of more than
five percent of any class of the  Company's  common  stock as of  September  30,
2003.


<TABLE>
<CAPTION>

-------------------------------------------------------------------------------------------------------------
    <S>                         <C>                             <C>                    <C>
         (1)                          (2)                              (3)                    (4)
    Title of Class              Name and Address                Amount and Nature        Percentage of
                                of Beneficial Owner             of Beneficial Owner         Ownership
-------------------------------------------------------------------------------------------------------------


    Common A                    Inamco Services Corp.*              12,947,487               46.91%
                                   801 Montrose Ave.
                               South Plainfield, NJ  07080

    Common A                   Advanced Diagnostics Inc.*            7,976,393               28.89%
                                   801 Montrose Ave.
                               South Plainfield, NJ  07080
</TABLE>

Security ownership of management.

     The following table provides information  pertaining to shares beneficially
owned by all directors and nominees.


<TABLE>
<CAPTION>


-------------------------------------------------------------------------------------------------------------
    <S>                        <C>                             <C>                     <C>
         (1)                          (2)                              (3)                    (4)
    Title of Class              Name and Position               Amount and Nature        Percentage of
                                of Beneficial Owner             of Beneficial Owner         Ownership
-------------------------------------------------------------------------------------------------------------

     Common A                   Varges George*                      21,923,880                79.43%
                               President/Secretary

</TABLE>

     Mr. Varges George is the sole  shareholder of Inamco  Services  Corp.,  and
Advanced  Diagnostics  Inc., as described  herein.  Accordingly,  Mr. George has
direct  control  of  approximately  79.43%  of  Inamco  International,   Corp.'s
outstanding  common shares of stock that is inclusive of 1,000,000  shares owned
directly in his name.

7. Follow-on Offering of Common Stock

     For the nine months ended September 30, 2003 , the Company has not recorded
and/or performed any secondary or private offering sale of securities.


8. Contingencies

     On October 29, 2003, the Company,  its subsidiaries and Varges George,  the
principal  shareholder  of the Company  were sued by H. Neil Broder  based on an
alleged  breach of contract  claim.  Mr. Broder  alleges that he provided  legal
services  to Mr.  George to wit  providing  Mr.  Broder  with a check  which had
insufficient  funds. Mr. George has repaid the plaintiff the amount of the check
that was  insufficient  and is  currently  negotiating  to settle  the claim for
damages incurred.

                                       7
<PAGE>


     The Company has recently  received notice from a shareholder of the Company
that such  shareholder  alleges that the Company has filed false and  misleading
documents  with the SEC.  Such  shareholder  claims  that the Company had assets
pursuant to its merger with Omni  Assets,  Inc. in 1999.  To date no lawsuit has
been  commenced in this matter and the Company  believes that these  allegations
have no merit.

9. Subsequent Events


     In June 2003, the Board  approved and announced a 1-for-1000  reverse stock
split.  The Record date for said split was  September  1, 2003 and a holder of a
majority of the  outstanding  shares approved such split. As of the Record Date,
our authorized  capitalization  consisted of 50,000,000  shares of common stock,
par value  $0.00001 per share (the "Common  Stock"),  of which  27,600,000  were
issued and outstanding. Pursuant to the reverse stock split, 1,000 shares of our
Common Stock were converted into one share of Common Stock and there were 27,600
shares issued and outstanding after the split. The effective date of the reverse
stock split was October 2, 2003.

     The following table presents pro-forma weighted average  outstanding shares
and loss per share as if the reverse split were effectuated before September 30,
2003
<TABLE>
<CAPTION>


                                                   Inception
                                                 Jan 17, 1983 to          Three Months Ended               Nine Months Ended
                                                  Sept. 30,2003   Sept. 30, 2003   Sept. 30, 2002   Sept. 30, 2003   Sept. 30, 2002
                                                  -------------   --------------   --------------   --------------   --------------

<S>                                              <C>             <C>              <C>              <C>             <C>
Net Loss ......................................   $     (53,086)  $       (8,031)  $          (39)  $      (17,463)  $         (539)
                                                  -------------   --------------   --------------   --------------   --------------

Weighted Average Number of Shares
Outstanding ...................................          14,932           27,600           27,600           27,600           27,600
                                                  -------------   --------------   --------------   --------------   --------------

Loss Per Share ................................   $       (3.56)  $        (0.29)  $        (0.00)  $        (0.63)  $        (0.02)
                                                  -------------   --------------   --------------   --------------   --------------

</TABLE>


     On October 29, 2003,  pursuant to an Agreement and Plan of Acquisition  the
company acquired all of the outstanding shares of Medicos Laboratories,  Inc., a
Delaware  corporation for the issuance of 1,975,000 shares to Varges George, the
sole  shareholder  of Medicos  Laboratories,  Inc.  In addition to the merger of
Medicos  Laboratories,  Inc., on October 29, 2003,  pursuant to an Agreement and
Plan of  Acquisition  the  company  acquired  all of the  outstanding  shares of
Advanced Diagnostics,  Inc. a Delaware corporation for the issuance of 3,000,000
shares to Varges George, the sole shareholder of Advanced Diagnostics,  Inc. Mr.
George is also the principal  shareholder and President of Inamco International,
Inc.  Pursuant to these  Agreements,  Medicos  Laboratories,  Inc.  and Advanced
Diagnostics, Inc. became our wholly owned subsidiaries.


ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS


     This  discussion  and  analysis  should  be read in  conjunction  with  our
financial  statements  and  accompanying  notes  included in this report and the
financial statements and notes thereto for the interim period ended December 31,
2002 included in the Company's Form 10, as amended, as well as Form 10-KSB filed
with the Securities and Exchange Commission on April 15, 2003.

     Operating results are not necessarily  indicative of results that may occur
in future periods.


     This  discussion  and analysis  contains  forward-looking  statements  that
involve risks,  uncertainties  and assumptions.  Inamco assumes no obligation to
update any  forward-looking  statement contained in this Form 10.The Company has
had no change in its financial  condition as a result of any operations,  nor is
there  any  liquidity,  capital  resources,  results  of  operation,   financial
statements for any interim periods,  material changes in financial position,  or
material changes from the result of operations.

                                       8
<PAGE>

     Certain statements contained in this report on Form 10-QSB and other public
statements that are not historical facts,  including those statements that refer
to our  plans,  goals,  objectives,  expectations,  strategies,  intentions  and
beliefs,  constitute  "forward-looking  statements"  within  the  meaning of the
Private  Securities  Litigation  Reform  Act of  1995.  In some  cases,  you can
identify  forward-looking  statements  by  terminology  such as  "will,"  "may,"
"should,"   "expects,"   "plans,"   "anticipates,"    "believes,"   "estimates,"
"predicts,"  "potential,"  "continue,"  or similar  words.  You should not place
undue reliance on these  forward-looking  statements.  These statements  involve
risks  and  uncertainties  that may  cause  actual  results  or events to differ
materially from those expressed or implied in our forward-looking statements. We
assume no obligation to update these forward-looking statements as circumstances
change in the future.


     Inamco as of  September  30,  2003,  was a company  that was in search of a
merger/acquisition  candidate in the generic pharmaceutical sector. The Company,
being in its developmental  stage, had no resources.  Consequently,  the Company
needed,  and still  needs  infusions  of working  capital  either in the form of
equity investments,  loans or otherwise, in order to operate as a pharmaceutical
concern.

     As of September  30, 2003,  the Company had yet to commence any  operations
and was seeking a proper merger and acquisition  candidate to operate within the
pharmaceutical drug sector.

     Generic pharmaceuticals, as a whole, have the same chemical and therapeutic
properties as their brand-named counterparts. Although typically less expensive,
they are  required to meet the same  governmental  standards  as the  brand-name
drug, and most must receive approval from the appropriate  regulatory  authority
prior to manufacture and sale.

     As  of   September   30,   2003,   Inamco  had  not  spent  any  monies  on
company-sponsored  research and development activities,  and at that time, there
were no plans to do so in the foreseeable future.


RESULTS OF OPERATIONS

NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002

Revenues

     None. For the nine and three months ended  September 30, 2003 and 2002, the
Company has had no revenue.

Research and Development

     None. For the nine and three months ended  September 30, 2003 and 2002, the
Company has performed no research and development.

General and Administrative

     General and administrative expenses are minimal, and for the nine and three
months ended September 30, 2003 were $17,463 and $8,031 respectively compared to
$539 and $39 for the same periods in September 2002.  General and administrative
expenses consist primarily of supporting  administration of a public company and
some professional fees. We expect that our general and  administrative  expenses
will increase substantially once a merger and/or acquisition is consummated,  in
order to support our growth and requirements as a public company.

Non-Cash Stock-Based Compensation Charges

    None. For the nine months ended September 30, 2003, the Company has not had
any non-cash stock based deferred compensation.

Other Income, net

     None.  For the nine  months  ended  September  30,  2003 and the year ended
December 31, 2002, the Company has had no other income.

                                       9
<PAGE>

LIQUIDITY AND CAPITAL RESOURCES

     As of September  30, 2003, we have  accumulated  a deficit of $53,087.  Our
accumulated  deficit is the result of expenses  incurred in connection  with the
acquisition of the Company and general and administrative  expenses. To date, we
have funded our operations  solely  through loans from the majority  shareholder
and president of the Company, Mr. Varges George.

     As of September 30, 2003, we had $92 in cash and cash equivalents  compared
to $927 in cash and cash equivalents as of December 31, 2002.

     Net cash used for  operations  during the nine months ended  September  30,
2003 was  $12,889  compared  to $2,192  for the same  period  in 2002.  Net cash
provided by  Officers/Shareholders  was  approximately  $12,054  during the nine
months  ended  September  30,  2003  compared to $2,168 for the same period last
year.


     As of September  30,  2003,  our Company had no business  and/or  operating
history, and the success of the Company depended and currently depends, in part,
upon the successful  performance of the president and chief  operating  officer,
Mr. Varges George.  At present,  the Company can make no assurances that it will
ever have be profitable or achieve positive cash flow from operations.


     The funding  requirements of the Company may change at any time, and future
capital  requirements  will depend on  numerous  factors,  including  scientific
progress,  additional  personnel costs,  progress in drug testing,  the time and
cost related to proposed regulatory  approvals,  if any, and the costs of filing
certain  applications.  We  cannot  assure  you that  adequate  funding  will be
available  to us or,  if  available,  that such  funding  will be  available  on
acceptable  terms. Any shortfall in funding could cause  detrimental  results to
our Company's present business and future growth plans.

Item 3.  CONTROLS AND PROCEDURES

(a)      Evaluation of Disclosure  Controls and  Procedures.
         ---------------------------------------------------
Within the 90 daysprior to the date of this report,  Inamco  International Corp.
carried out an evaluation,  under the supervision and with the  participation of
the Company's management,  including the Company's Chief Executive and Principal
Accounting  Officer,  of the  effectiveness  of the design and  operation of the
Company's  disclosure  controls  and  procedures  pursuant to Exchange  Act Rule
13a-14. Based upon that evaluation, the Chief Executive and Principal Accounting
Officer  concluded  that the Company's  disclosure  controls and  procedures are
effective in timely alerting him to material information required to be included
in the Company's periodic SEC filings relating to the Company.

(b)      Changes in Internal Controls.
         -----------------------------
There were no significant changes in the Company's internal controls or in other
factors that could  significantly  affect these internal controls  subsequent to
the date of my most recent evaluation.

PART II. OTHER INFORMATION

Item 1.  Legal Proceedings.

     On October 29, 2003, the Company,  its subsidiaries and Varges George,  the
     principal  shareholder  of the Company were sued by H. Neil Broder based on
     an alleged  breach of contract  claim.  Mr. Broder alleges that he provided
     legal services to Mr. George to wit providing Mr. Broder with a check which
     had  insufficient  funds. Mr. George has repaid the plaintiff the amount of
     the check that was insufficient and is currently  negotiating to settle the
     claim for damages incurred.

     Advanced  Diagnostics,  Inc.,  a wholly  owned  subsidiary  of the  company
     effective October 29, 2003(see Note 9), recently received a letter from the
     Borough of South  Plainfield  stating that the it owes real estate taxes of
     approximately $100,000. To date no action has been taken in this matter and

                                      10
<PAGE>

     the Company is prepared to pay such amount in full and is negotiating  with
     the Township to determine the final amount owed.

     The Company has recently  received notice from a shareholder of the Company
     that  such  shareholder  alleges  that the  Company  has  filed  false  and
     misleading documents with the SEC. Such shareholder claims that the Company
     had assets  pursuant to its merger with Omni Assets,  Inc. in 1999. To date
     no lawsuit has been commenced in this matter and the Company  believes that
     these allegations have no merit.

Item 2.  Changes in Securities.

     None

Item 3.  Defaults Upon Senior Securities.

     Not Applicable

Item 4.  Submission of Matters to a Vote of Security Holders.

     On September 1, 2003,  a holder of the majority of the  outstanding  shares
     approved a 1-1,000 reverse split of the Company's outstanding shares.


Item 5.  Other Information.

     None

Item 6.  Exhibits and Reports of Form 8-K.

     On August 1, 2003,  we filed an  amendment to a Form 8K dated June 18, 2003
     based on a change in our accountants.




                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.
                                          INAMCO INTERNATIONAL, CORP.


Dated:  November 19, 2003                 By:   /s/ VARGES GEORGE
                                             ------------------------
                                                 Name: Varges George
                                            Title: President, Chief Executive
                                           Officer and Chief Financial Officer




                                       11

<PAGE>